ProfileGDS5678 / 1429909_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 71% 71% 75% 71% 72% 71% 71% 70% 71% 72% 71% 67% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2444969
GSM967853U87-EV human glioblastoma xenograft - Control 24.4694471
GSM967854U87-EV human glioblastoma xenograft - Control 34.47371
GSM967855U87-EV human glioblastoma xenograft - Control 45.0895975
GSM967856U87-EV human glioblastoma xenograft - Control 54.4202571
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4910672
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4726271
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4873771
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4046770
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.461771
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5463572
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4635271
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1079667
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4624471